OR WAIT null SECS
FDA revisits who can get Biogen's controversial Alzheimer's drug
July 13, 2021
The therapy for opioid-induced constipation has no restrictions on an unidentified national formulary that serves these Blues plans.
The review will determine whether there should be a national Medicare coverage policy for the Alzheimer’s therapy.
July 12, 2021
Commercial insurers are beginning to provide coverage information on Biogen’s controversial therapy.
July 09, 2021
The specialty pharmacy is licensed in all 50 states.
Orally dissolving film formulation of riluzole is now available for patients who have difficulty swallowing.
July 08, 2021
The prescribing information for Aduhelm now specifies its use in patients with a mild form of the disease.
July 02, 2021
Coverage now includes 85% of commercial lives.
Formulary adoption is a key step in achieving sales pull through starting in 2022, company officials said.
July 01, 2021
Patients are being offered $500 to make the switch.
June 30, 2021
A recent study finds that the approval of a biosimilar was associated with a change in the trajectory of net prices.
